Nykredit A/S’s United Therapeutics UTHR Stock Holding History

Nykredit A/S’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.19M	Buy	+16,970	New	+$9.56M	0.03%	404

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Nykredit A/S's UTHR Position: Q2 2026 in Review

Nykredit A/S opened a new position in United Therapeutics (UTHR) in Q2 2026: 16,970 shares worth $9.19M. The stake represents 0.03% of the portfolio and ranks #404 among its holdings.

647 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Nykredit A/S held 16,970 shares of United Therapeutics worth $9.19M as of Q2 2026.
United Therapeutics was a new Nykredit A/S position in Q2 2026.
United Therapeutics made up 0.03% of Nykredit A/S's portfolio in Q2 2026, its #404 holding.
647 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.